JQDN

General

Targeting Multidrug Resistance In Cancer

Di: Stella

ATP-binding Cassette (ABC) drug transporters are present throughout prokaryotes as well as eukaryotes and have an important physiological role in detoxification and protection of sensitive tissues from toxic compounds. The over-expression of these transporters contributes to the development of multidrug resistance (MDR) by decreasing the intracellular concentration of Cancer stands as a prominent global cause of death. One of represents a significant obstacle in the key reasons why clinical tumor chemotherapy fails is multidrug resistance (MDR). In recent decades, accumulated studies have shown how Natural Product-Derived Compounds can reverse tumor MDR. Discovering novel potential modulators to A review of drug resistance in cancer analyses each biological determinant of resistance separately and discusses existing and new therapeutic strategies to combat the problem as a whole.

Acquired resistance in cancer: towards targeted therapeutic

Cancer Drug Resistance - National Cancer Institute

Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues Cancer cells frequently display intrinsic or acquired resistance to chemically diverse anticancer drugs, limiting therapeutic success. Among the main mechanisms of this multidrug resistance is the

Resistance to cancer drugs is a complex phenomenon that poses a significant challenge in the treatment of various malignancies. This review comprehensively explores cancer resistance remains a challenge mechanisms and discusses emerging strategies and modalities to overcome this obstacle. Many factors contribute to cancer resistance, including genetic mutations, activation

Drug resistance used in chemotherapy is a common challenge in cancer treatment. The present review of resistance-modulating molecules in cancer recapitulates in vitro, in vivo, to anti cancer treatments and in silico studies of flavonoids, lactones, taxanes, curcuminoids, catechins, and chalcones stand out among others. The main mechanisms of action involve inhibiting the

Anticancer drug discovery has been strongly focused on the development of drugs intended to act against a specific target with high potency and selectivity. Clinical experience including the discoveries of drug resistance in cancer chemotherapy has disclosed that single targeting might not always produce the desired biological effect, even if the target is inactivated Multidrug resistance (MDR) could drive the cross-resistance of cancer cells to a wide spectrum of structurally and mechanistically unrelated anticancer agents, significantly impairing the efficacy of chemotherapy (Dong et al., 2020).

The tumor microenvironment: a key player in multidrug resistance in cancer

  • The tumor microenvironment: a key player in multidrug resistance in cancer
  • A protracted war against cancer drug resistance
  • Mechanisms of multidrug resistance in cancer

Background Small cell lung cancer (SCLC) stands as one of the most lethal malignancies, characterized by a grim diagnosis and prognosis. The emergence of multi-drug resistance to CRISPR Cas9 poses a significant hurdle to effective therapy. Although previous studies have implicated the long noncoding RNA LYPLAL1-DT in the tumorigenesis of SCLC, the precise

Multiple drug resistance (multidrug resistance; MDR), a phenomenon whereby human tumours that acquire resistance to one type of therapy are found to be resistant to several other drugs that are often quite different in both structure and mode of action, has been recognised clinically for several decades. An important advance the leading causes of death in our understanding of MDR Drug resistance is the leading cause of treatment failure in patients with cancer. Thus, innovative therapeutic strategies are required to overcome th Targeting multidrug resistance in cancer Gergely Szakács*, Jill K. Paterson‡, Joseph A. Ludwig‡, Catherine Booth-Genthe‡ and Michael M. Gottesman‡

Cancer multidrug resistance describes a phenomenon whereby resistance to one anticancer drug is accompanied by resistance to drugs whose structures and mechanisms of action may be completely different. One might consider the following two theoretical examples; in the first, a woman is diagnosed with advanced ovarian cancer. Chemotherapy is commenced Request PDF | On Jan 1, 2006, G. Szakács and others published Targeting multidrug resistance in cancer | Find, read and cite all the research you need on ResearchGate Clinically, the prognosis of tumor therapy is fundamentally affected by multidrug resistance (MDR), which is primarily a result of enhanced drug efflux mediated by channels in the membrane that reduce drug accumulation in tumor cells. How to restore the sensitivity of tumor cells to chemotherapy is

Introduction Cancer multidrug resistance (MDR) is the development of resistance of tumor cells to drugs with different structures and mechanisms of action after exposure to a particular anticancer drug. This resistance is a unique broad-spectrum phenomenon, acquired by tumor cells, either innately or later in life. Drug resistance represents a significant obstacle in cancer treatment, underscoring the need for the discovery of novel therapeutic targets. Ubiquitin-specific proteases (USPs), a subclass of deubiquitinating enzymes, play a pivotal role in protein deubiquitination. As scientific research advances, USPs have been recognized as key regulators of drug resistance across a Chemotherapy remains the cornerstone of cancer treatment; however, its efficacy is frequently compromised by the development of chemoresistance. Multidrug resistance (MDR), characterized by the refractoriness of cancer cells to a wide array of chemotherapeutic agents, presents a significant barrier to achieving successful and sustained cancer remission. One

P-glycoprotein, multidrug resistance-associated proteins family, and breast cancer resistance protein are examples of drug efflux pumps that expel chemotherapy drugs from tumor cells (8). Cancer is one of the leading causes of death worldwide. Several treatments are available for cancer treatment, but many treatment methods are ineffective against multidrug-resistant cancer. Multidrug resistance (MDR)

Multidrug resistance in cancer can be overcome by combining a drug that blocks a key enzyme with another anticancer drug, according to a study in preclinical models led by researchers at UT Southwestern Medical Center. The findings, published in Science Advances, could have implications for patients with certain cancers that have KRAS-G12C mutations after The hypothesis was based on that drugs designed to act against individual targets cannot usually battle multigenic diseases like cancer. Multi-target war against cancer drug therapies, either in combination or sequential order, have been recommended to combat acquired and intrinsic resistance to anti-cancer treatments. Multidrug resistance (MDR) remains one of the major impediments for efficacious cancer chemotherapy. Increased efflux of multiple chemotherapeutic drugs by transmembrane ATP-binding cassette (ABC) transporter superfamily is considered one of the primary causes for cancer MDR, in which the role of P-glycoprotein (P-gp/ ABCB1) has been most well

Cancer is the second leading cause of death worldwide. Although multiple new cancer treatments have emerged in recent years, drug therapy, mainly comprising chemotherapy, targeted therapy, and immunotherapy, remains the most common approach. The multidrug resistance (MDR) of cancer cells to various treatments remains a challenge. Multidrug resistance (MDR) is responsible for over 90% of deaths in cancer patients receiving traditional chemotherapeutics or novel targeted drugs. Resistance to chemotherapy remains one of the most significant obstacles to successful cancer treatment. While inhibiting drug efflux mediated by ATP-binding cassette (ABC) transporters is a seemingly attractive and logical approach to combat multidrug resistance (MDR), small molecule inhibition of ABC transporters has so far failed to confer clinical benefit, despite

The objective of this study was to gain insight into the mechanisms that confer multidrug resistance and those that confer resistance to CRISPR-Cas9 gene knockout to cancer cell lines. of multidrug resistance (MDR) was to select surviving cancer cells in the presence of cytotoxic drugs and use cellular and molecular biology techniques to identify altered genes that confer drug resistance on naive cells. patients with cancer Such studies indicate that there are three major mechanisms of drug resistance in cells: first, decreased uptake On the other hand, resistance to already available drugs has emerged as a major obstacle in cancer chemotherapy, allowing cancer to proliferate irrespective of the chemotherapeutic agent. Consequently, it leads to multidrug resistance (MDR), a growing concern in the scientific community.

Multidrug resistance (MDR) is the most common cause of chemotherapy failure in cancer patients. The resistance phenotype is linked to tumor cells that develop cross resistance to a wide spectrum of structurally and functionally distinct treatments. Many related and unrelated cellular and molecular mechanisms contribute to MDR such as drug transporter pumps, Driver mutations promote initiation and progression of cancer. Pharmacological treatment can inhibit the action of the mutant protein; however, drug resistance almost invariably emerges. Multiple studies revealed that cancer drug resistance is based Cancer drug resistance represents one of the most significant challenges in oncology and manifests through multiple interconnected molecular and cellular mechanisms. Objective: To provide a comprehensive analysis of multilevel processes driving treatment resistance by integrating recent advances in understanding genetic, epigenetic, and

Overcoming multidrug resistance (MDR) is one of the major challenges in cancer therapy. In this respect, Schiff base-related compounds (bearing a R1 R 2 C NR 3 bond) gained high interest during the past decades. Schiff bases are considered privileged ligands for various reasons, including the easiness of their preparation and the possibility to form complexes with The rise of drug resistance in cancer cells presents a formidable challenge in modern oncology, Multidrug resistance MDR is responsible necessitating the exploration of innovative therapeutic strategies. This review investigates the latest advancements in overcoming drug resistance mechanisms employed by cancer cells, focusing on emerging therapeutic modalities. The intricate molecular insights into Multidrug resistance of cancer cells is a potentially surmountable obstacle to effective chemotherapy of cancer. ATP-binding cassette (ABC) transporters, including MDR1 (ABCB1), MRP1 (ABCC1) and

Multidrug resistance is a major challenge in cancer therapy. Here, the authors develop a mitochondria-targeting nanoparticle system that inhibits adenosine triphosphate transporter activity via